Skip to main content

Table 2 Clinical features and laboratory findings differences between severe and non-severe patients

From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study

Clinical features All (n = 103) Non-severe (n = 67) Severe (n = 36) P-value
Age 66.0 (24.0–90.0) 65.0 (43.0–90.0) 70.0 (24.0–87.0) 0.004
Gender     0.097
 Female 47 (45.6%) 35 (52.2%) 12 (33.3%)  
 Male 56 (54.4%) 32 (47.8%) 24 (66.7%)  
Smoking 20 (19.4%) 8 (11.9%) 12 (33.3%) 0.017
Comorbidities     
 Diabetes 14 (13.6%) 5 (7.5%) 9 (25%) 0.018
 Hypertension 37 (35.9%) 22 (32.8%) 15 (41.7%) 0.396
 Heart disease 11 (10.7%) 4 (6.0%) 7 (19.4%) 0.047
Symptoms     
 Fever 73 (70.9%) 45 (67.2%) 28 (77.8%) 0.363
 Cough 70 (68.0%) 49 (73.1%) 21 (58.3%) 0.183
 Dyspnea 24 (23.3%) 9 (13.4%) 15 (41.7%) 0.003
 Vomiting 5 (4.9%) 2 (3.0%) 3 (8.3%) 0.340
 Diarrhea 7 (6.8%) 3 (4.5%) 4 (11.1%) 0.235
Laboratory findings     
 WBC (× 109/L) 5.29 (1.90–25.10); n = 100 4.77 (1.90–25.10); n = 65 7.16 (2.00–18.80); n = 35  < 0.001
 Neutrophil (× 109/L) 3.49 (0.67–22.40); n = 100 3.00 (0.67–22.40); n = 65 5.27 (1.03–17.36); n = 35  < 0.001
 Lymphocyte (× 109/L) 1.06 (0.22–2.89); n = 100 1.23 (0.33–2.62); n = 65 0.80 (0.22–2.89); n = 35 0.003
 NLR 2.93 (0.64–32.23); n = 100 2.29 (0.64–18.39); n = 65 6.93 (1.20–32.23); n = 35  < 0.001
 Monocytes (× 109/L) 0.43 (0.11–9.90); n = 72 0.41 (0.11–9.90); n = 52 0.50 (0.14–1.04); n = 20 0.297
 Eosnophils (× 109/L) 0.07 (0.00–0.90); n = 72 0.08 (0.00–0.51); n = 52 0.03 (0.00–0.90); n = 20 0.007
 Basophils (× 109/L) 0.02 (0.00–0.11); n = 72 0.02 (0.00–0.11); n = 52 0.02 (0.00–0.05); n = 20 0.09
 RBC (× 1012/L) 3.95 (2.03–5.77); n = 73 4.01 (2.03–5.14); n = 52 3.53 (2.63–5.77); n = 21 0.116
 HB (g/L) 116.00 (68.00–154.00); n = 73 119.00 (68.00–154.00); n = 52 102.00 (79.00–154.00); n = 21 0.065
 PLT (× 109/L) 203.00 (53.00–431.00); n = 72 205.00 (67.00–431.00); n = 52 190.00 (53.00–312.00); n = 20 0.606
 CRP (mg/L) 2.52 (0.14–280.32); n = 90 1.39 (0.14–137.52); n = 58 42.59 (0.05–280.32); n = 32  < 0.001
 ALT (U/L) 19.17 (4.50–131.20); n = 97 19.05 (4.50–131.20); n = 64 20.70 (6.00–100.30); n = 33 0.87
 AST (U/L) 21.70 (10.00–147.20); n = 84 20.45 (10.00–147.20); n = 52 26.70 (12.00–92.60); n = 32 0.014
 Total protein (g/L) 64.99 (53.70–87.58); n = 71 65.50 (55.45–87.58); n = 51 60.89 (53.70–78.97); n = 20 0.04
 Albumin (g/L) 37.29 (23.60–48.00); n = 71 38.14 (23.60–48.00); n = 51 32.61 (25.30–43.50); n = 20 0.002
 Globulin (g/L) 28.00 (17.31–46.24); n = 71 27.30 (17.31–40.49); n = 51 28.20 (24.00–46.24); n = 20 0.818
 A/G 1.30 (0.39–2.20); n = 71 1.35 (0.39–2.20); n = 51 1.22 (0.71–1.46); n = 20 0.017
 Total bilirubin (umol/L) 10.32 (4.20–44.58); n = 70 10.23 (4.20–33.46); n = 51 11.70 (6.00–44.58); n = 19 0.152
 Direct Bilirubin (umol/L) 2.71 (0.00–23.90); n = 70 2.50 (0.00–14.20); n = 51 3.86 (0.00–23.90); n = 19 0.053
 Indirect bilirubin (umol/L) 7.39 (2.99–26.42); n = 70 7.32 (3.00–26.42); n = 51 7.90 (2.99–22.68); n = 19 0.468
 BUN (umol/L) 4.67 (2.68–29.61); n = 68 4.62 (2.68–29.61); n = 49 5.47 (2.93–18.77); n = 19 0.114
 Creatinine (umol/L) 57.72 (13.25–345.35); n = 70 58.17 (31.60–345.35); n = 50 55.15 (13.25–145.39); n = 20 0.559
 Uric acid (umol/L) 268.01 (100.00–275.95)); n = 69 304.73 (151.56–575.95); n = 50 163.00 (100.00–547.00); n = 19  < 0.001
 ALP (U/L) 71.10 (42.59–493.30); n = 70 67.80 (42.59–493.30); n = 51 74.60 (55.16–238.00); n = 19 0.212
 γ-GT (U/L) 26.47 (8.15–263.60); n = 70 26.30 (8.15–263.60); n = 51 33.62 (11.02–239.60); n = 19 0.262
 CK (U/L) 48.40 (10.90–195.90); n = 55 52.67 (16.89–116.73); n = 37 43.14 (10.90–195.90); n = 18 0.244
 CKMB (U/L) 7.80 (0.01–54.60); n = 68 7.61 (0.01–54.60); n = 50 7.85 (2.28–49.70); n = 18 0.416
 LDH (U/L) 179.90 (2.17–761.70); n = 69 169.13 (2.17–761.70); n = 50 209.66 (116.20–702.30); n = 19 0.001
 ɑ-HBDH (U/L) 133.59 (87.75–701.40); n = 66 126.96 (87.75–701.40); n = 48 169.50 (99.79–604.40); n = 18 0.005
 D-dimer (mg/L) 0.43 (0.02–27.94); n = 45 0.37 (0.07–4.97); n = 30 1.14 (0.02–27.94); n = 15 0.001
 NT-proBNP (U/L) 30.77 (0.01–515.18); n = 22 11.33 (0.01–112.76); n = 11 60.90 (23.94–515.81); n = 11 0.001
 Procalcitonin (ng/ml) 0.05 (0.02–0.90); n = 56 0.04 (0.02–0.45); n = 36 0.18 (0.02–0.90); n = 20  < 0.001
 IL-6 (pg/ml) 3.64 (1.50–3392.00); n = 50 2.84 (1.50–268.30); n = 33 29.99 (1.50–3392.00); n = 17 0.001
  1. WBC white blood cell, NLR leukocyte to lymphocyte ratio, RBC red blood cell, HB hemoglobin, PLT platelet, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, A/G albumin to globulin ratio, BUN blood urea nitrogen, ALP alkaline phosphatase, γ-GT gamma-glutamyl transpeptidase, CK creatine kinase, CKMB MB isoenzyme of creatine kinase, LDH lactate dehydrogenase, α-HBDH alpha-hydroxybutyric dehydrogenase, NT-proBNP N-terminal pro brain natriuretic peptide, IL-6 interleukin-6